The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...

“These are our neighbours. These are people who are working.” Mr Frost said he plans to meet Orlando-area mayors, law enforcement, judges and school leaders to encourage them to limit ...

For people with anxiety and depression, these conditions can feel like two sides of the same coin. Researchers are exploring how interventions could help alleviate the ups and downs of both disorders.

Chelsea boss Enzo Maresca has admitted to feeling 'shame' over Ben Chilwell's situation at Stamford Bridge, with the England defender having been frozen out of the first-team picture. Chilwell has ...

Ministers described the Elective Reform Plan, published by NHS England, as a “whole system approach” to hitting the 18-week referral to treatment target by the end of this Parliament.

The new plan also says abolishing automatic review appointments after treatment, offering them instead only to patients who request them, will free up a million appointments every year for ...

open image in gallery Sir Keir Starmer and Wes Streeting have promised the plan will bring maximum waiting times for treatment down to 18 weeks (PA Archive) Ahead of the speech, he said ...

As part of the elective reform plan, millions of people will receive quicker diagnosis and treatment to deliver routine care to nine in ten patients within 18 weeks. The ambitious new blueprint will ...

Govt will allow the mining companies that have paid conversion fees to handle low-grade iron ore dumps according to the declared quantity ...

Josh Gad rips the Band-Aid off in his forthcoming memoir, In Gad We Trust: A Tell-Some, proving that he’s so much more than just a musical Mormon and an animated snowman. The triple threat sat ...

Shares have plunged 75% this year. The Iselin, N.J., biopharmaceutical company said it plans to launch its treatment, Lytenava, in the United Kingdom and Germany, likely in the first half of 2025.

“Today marks a pivotal moment in our journey towards advancing a novel treatment option for the 20 million people 1 in the U.S. living with GAD. Building on our scientifically rigorous Phase 2b ...